ACAD ACADIA PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1070494 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.8%
TTM net income YoY38.7%
TTM EPS YoY36.8%
Revenue 3-yr CAGR23.9%
Net income 3-yr CAGR—
Margins
Gross margin90.5%
Operating margin10.2%
Net margin30.1%
FCF margin6.8%
EBITDA margin10.3%
Returns
ROE31.4%
ROA23.2%
ROIC (approx.)14.2%
Asset turnover0.77x
Leverage & solvency
Liabilities / assets22.7%
Debt / equity0.00x
Current ratio3.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.27x
Accruals ratio16.9%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.07B | $957.80M |
| Cost of revenue | $89.00M | $81.84M |
| Gross profit | $982.51M | $875.96M |
| R&D expense | $328.80M | $303.25M |
| SG&A expense | $548.89M | $488.43M |
| Operating income | $104.81M | $230.79M |
| Pretax income | $138.90M | $258.07M |
| Income tax | -$252.10M | $31.62M |
| Net income | $391.00M | $226.45M |
| EBITDA | $105.68M | $231.71M |
| EPS (basic) | 2.32 | 1.37 |
| EPS (diluted) | 2.30 | 1.36 |
| Weighted avg. shares (diluted) | 169.92M | 166.36M |
| Balance sheet | ||
| Cash & equivalents | $177.69M | $319.59M |
| Short-term investments | $641.99M | $436.40M |
| Receivables | $121.46M | $98.74M |
| Inventory | $111.37M | $91.69M |
| Current assets | $1.06B | $938.32M |
| PP&E, net | $7.51M | $4.21M |
| Intangibles | $108.89M | $119.78M |
| Total assets | $1.56B | $1.19B |
| Current liabilities | $277.11M | $394.87M |
| Total liabilities | $336.81M | $454.96M |
| Shareholders' equity | $1.23B | $732.79M |
| Shares outstanding | 170.31M | 166.71M |
| Cash flow statement | ||
| Operating cash flow | $109.84M | $157.72M |
| Capital expenditure | $4.69M | $523,000 |
| Free cash flow | $105.15M | $157.20M |
| Investing cash flow | -$302.56M | -$30.54M |
| Financing cash flow | $49.88M | $6.84M |
| Depreciation & amortization | $871,000 | $920,000 |
| Stock-based compensation | $52.13M | $67.05M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.